
  
    
      
        Background_NNP
        Plasminogen_NNP activator_NN inhibitor-_NN 1_CD (_( PAI-_NNP 1_LS )_) is_VBZ a_DT serine_NN
        proteinase_NN inhibitor_NN in_IN the_DT serpin_NN superfamily_RB [_NN 1_CD 2_CD 3_CD ]_NN ._.
        This_DT 50_CD kDa_NN glycoprotein_NN is_VBZ apparently_RB the_DT most_RBS important_JJ
        physiological_JJ inhibitor_NN of_IN tissue-type_JJ plasminogen_NN
        activator_NN (_( tPA_NN )_) and_CC of_IN urokinase_NN plasminogen_NN activator_NN
        (_( uPA_NN )_) ._. [_NN 4_CD ]_NN It_PRP was_VBD shown_VBN to_TO play_VB a_DT crucial_JJ role_NN in_IN the_DT
        regulation_NN of_IN vascular_NN thrombosis_NNS ,_, tumor_NN invasion_NN ,_,
        neovascularization_NN ,_, inflammation_NN and_CC wound_VBD healing_VBG ._. [_NN 5_CD 6_CD ]_NN
        Increased_VBN plasma_NN levels_NNS of_IN PAI-_NNP 1_CD were_VBD found_VBN to_TO be_VB
        correlated_JJ with_IN an_DT increased_VBN risk_NN for_IN cardiovascular_JJ
        diseases_NNS ._. [_NN 6_CD 7_CD 8_CD ]_NN The_DT essential_JJ function_NN of_IN PAI-_NNP 1_CD in_IN the_DT
        fibrinolytic_JJ system_NN has_VBZ been_VBN confirmed_VBN by_IN studies_NNS with_IN
        transgenic_JJ animals_NNS ._. [_NN 7_CD 9_CD ]_NN
        PAI-_NNP 1_CD shares_NNS a_DT 35_CD %_NN homology_NN with_IN 40_CD other_JJ serpins_NNS ._. [_NN 10_CD
        ]_NN The_DT X-_NNP ray_NN structure_NN of_IN active_JJ PAI-_NNP 1_CD [_NN 11_CD 12_CD ]_NN consists_VBZ of_IN
        three_CD sheets_NNS (_( A-C_NNP )_) ,_, nine_CD helices_NNS (_( a-i_JJ )_) and_CC a_DT reactive_JJ
        center_NN loop_NN (_( RCL_NNP )_) ._. The_DT RCL_NNP contains_VBZ the_DT residues_NNS Ser_NNP 331_CD to_TO
        Arg_NNP 356_CD (_( P_NN 16_CD -_: P_NN 10_CD '_POS )_) ,_, and_CC within_IN it_PRP there_EX is_VBZ a_DT peptide_NN loop_NN
        (_( Glu_NNP 351_CD to_TO Pro_FW 357_CD ,_, P_NN 5_CD '_POS -_: P_NN 11_CD '_POS )_) ,_, which_WDT is_VBZ defined_VBN as_IN the_DT
        distal_NN hinge_VB (_( Table_NNP 1_LS )_) ._. It_PRP should_MD be_VB noted_VBN that_IN the_DT
        placement_NN and_CC conformation_NN of_IN the_DT RCL_NNP in_IN active_JJ PAI-_NNP 1_CD is_VBZ
        quite_RB different_JJ from_IN that_DT of_IN latent_NN PAI-_NNP 1_CD ._. [_NN 13_CD ]_NN The_DT
        movement_NN of_IN the_DT distal_NN hinge_VB and_CC the_DT insertion_NN of_IN the_DT RCL_NNP
        into_IN sheet_NN A_DT as_JJ strand_NN 4_CD A_DT (_( s_VBZ 4_CD A_DT )_) should_MD take_VB place_NN during_IN
        the_DT transition_NN from_IN the_DT active_JJ into_IN the_DT latent_NN form_NN of_IN
        PAI-_NNP 1_CD ._.
        The_DT catalytic_JJ center_NN of_IN tPA_NN interacts_NNS with_IN the_DT reactive_JJ
        site_NN of_IN PAI-_NNP 1_CD with_IN concominant_NN formation_NN of_IN 1_CD :_: 1_CD molar_NN ,_,
        SDS-stable_NNP complex_NN ._. The_DT P_NN 1_CD (_( Arg_NNP 346_CD )_) residue_NN in_IN the_DT RCL_NNP of_IN
        PAI-_NNP 1_CD is_VBZ an_DT essential_JJ determinant_NN for_IN its_PRP$ target_NN
        specificity_NN and_CC inhibitory_NN activity_NN ._. [_NN 14_CD 15_CD ]_NN Since_IN many_JJ
        serpins_NNS with_IN identical_JJ amino_JJ acid_NN residue_NN at_IN P_NN 1_CD position_NN
        display_NN different_JJ specificities_NNS ,_, it_PRP is_VBZ unlikely_JJ that_IN the_DT P_NN 1_CD
        residue_NN is_VBZ the_DT sole_JJ determinant_NN for_IN target_NN protease_NN
        specificity_NN ,_, other_JJ regions_NNS of_IN PAI-_NNP 1_CD may_MD also_RB affect_VB its_PRP$
        specificity_NN toward_IN target_NN proteases_NNS ._. The_DT variable_JJ region_NN in_IN
        serine_NN proteases_NNS domain_NN determines_VBZ their_PRP$ specificity_NN for_IN
        PAI-_NNP 1_CD ._. Alignment_NNP of_IN variable_JJ region_NN 1_CD of_IN the_DT serine_NN
        proteases_NNS shows_VBZ a_DT remarkable_JJ correlation_NN between_IN the_DT
        composition_NN of_IN this_DT area_NN and_CC their_PRP$ susceptibility_NN to_TO
        inhibition_NN by_IN PAI-_NNP 1_CD as_IN shown_VBN in_IN Table_NNP 2_CD ._. [_NN 16_CD ]_NN Both_DT tPA_NN
        and_CC uPA_NN ,_, the_DT target_NN proteases_NNS of_IN PAI-_NNP 1_CD ,_, contain_VBP a_DT
        relatively_RB extensive_JJ variable_JJ region_NN 1_CD ,_, consisting_VBG of_IN four_CD
        to_TO five_CD positively_RB charged_VBN amino_JJ acid_NN residues_NNS present_JJ at_IN
        identical_JJ position_NN ._. Plasmin_NNP and_CC thrombin_NN with_IN moderate_JJ
        reactivity_NN toward_IN PAI-_NNP 1_CD have_VBP relatively_RB short_JJ variable_JJ
        regions_NNS which_WDT contain_VBP only_RB two_CD to_TO three_CD positively_RB charged_VBN
        residues_NNS ._. For_IN example_NN ,_, positively_RB charged_VBN amino_JJ acids_NNS in_IN
        the_DT variable_JJ region_NN of_IN tPA_NN ,_, uPA_NN and_CC thrombin_NN play_NN dominant_JJ
        roles_NNS in_IN the_DT specific_JJ interaction_NN with_IN PAI-_NNP 1_CD ._. [_NN 17_CD 18_CD 19_CD ]_NN
        Furthermore_RB ,_, Glu_NNP 350_CD (_( P_NN 4_CD '_POS )_) of_IN PAI-_NNP 1_CD has_VBZ been_VBN shown_VBN to_TO
        mediate_VB the_DT interactions_NNS with_IN tPA_NN ._. [_NN 18_CD ]_NN
        In_IN this_DT study_NN ,_, By_IN producing_VBG wtPAI-_NN 1_CD and_CC several_JJ single_JJ
        site_NN mutations_NNS in_IN the_DT distal_NN hinge_VB of_IN PAI-_NNP 1_CD in_IN a_DT
        baculovirus_JJ expression_NN system_NN ,_, we_PRP were_VBD able_JJ to_TO find_VB out_RP the_DT
        role_NN of_IN the_DT distal_NN hinge_VB in_IN conformational_NN transition_NN of_IN
        PAI-_NNP 1_CD and_CC to_TO elucidate_NN the_DT role_NN of_IN Glu_NNP 351_CD in_IN PAI-_NNP 1_CD for_IN
        serine_NN protease_NN specificities_NNS ._.
      
      
        Results_NNS
        
          Characterization_NNP of_IN wtPAI-_NN 1_CD
          To_TO confirm_VB the_DT validity_NN of_IN recombinant_JJ PAI-_NNP 1_CD as_IN a_DT
          model_NN to_TO study_VB the_DT native_JJ inhibitor_NN secreted_JJ from_IN human_JJ
          fibrosarcoma_NN cells_NNS ,_, we_PRP compared_VBD the_DT recombinant_JJ PAI-_NNP 1_CD and_CC
          the_DT fibrosarcoma_NN PAI-_NNP 1_CD first_JJ by_IN SDS-PAGE_NNP and_CC immunoblot_NN
          with_IN anti-_NN PAI-_NNP 1_CD monoclonal_NN antibodies_NNS ._. The_DT molecular_JJ
          weight_NN of_IN wtPAI-_NN 1_CD was_VBD found_VBN to_TO be_VB lower_JJR than_IN native_JJ PAI-_NNP 1_CD
          (_( ~_NN 50_CD kDa_NN ,_, Fig_NNP ._. 1_LS B_NNP )_) ._. We_PRP assumed_VBD that_IN this_DT is_VBZ due_JJ to_TO a_DT
          lower_JJR (_( probably_RB different_JJ )_) extent_NN of_IN glycosylation_NN in_IN the_DT
          baculovirus_JJ expression_NN system_NN ._. Indeed_RB ,_, when_WRB both_DT proteins_NNS
          were_VBD deglycosylated_JJ with_IN N-_NNP glycanase_NN they_PRP were_VBD found_VBN to_TO
          have_VB an_DT essentially_RB identical_JJ M_NNP ._. W_NNP ._. (_( ~_NN 48_CD kDa_NN )_) and_CC to_TO
          cross-react_JJ immunochemically_RB (_( Fig_NNP ._. 1_LS B_NNP )_) ._. Furthermore_RB ,_, when_WRB
          this_DT wtPAI-_NN 1_CD was_VBD chromatographed_JJ on_IN heparin-_NN Sepharose_NNP it_PRP
          was_VBD found_VBN to_TO be_VB >_NN 98_CD %_NN pure_JJ by_IN silver_NN staining_VBG of_IN the_DT
          gel_NN (_( Fig_NNP ._. 1_LS Alane_NNP 2_LS )_) ._.
          Interestingly_RB ,_, the_DT specific_JJ inhibitory_NN activity_NN of_IN
          wtPAI_NN was_VBD 63_CD ±_NN 15_CD U_NNP /_NN ug_NN just_RB after_IN purification_NN ,_, and_CC was_VBD
          increased_VBN to_TO 84_CD ±_NN 21_CD U_NNP /_NN ug_NN after_IN denatured_JJ by_IN 6_CD M_NNP Gdn-_NNP HCl_NNP
          and_CC refolded_JJ in_IN 50_CD mM_NN sodium_NN acetate_NN (_( pH_NN 5_CD ._. 6_CD )_) at_IN 4_CD °_NN C_NNP ._. In_IN
          contrast_NN ,_, the_DT specific_JJ activity_NN of_IN the_DT fibrosarcoma_NN PAI-_NNP 1_CD
          was_VBD only_RB 5_CD ±_NN 3_CD U_NNP /_NN ug_NN before_IN activation_NN ,_, and_CC was_VBD only_RB
          increased_VBN to_TO 45_CD ±_NN 16_CD U_NNP /_NN μg_NN after_IN denaturing_VBG and_CC refolding_VBG ._.
          The_DT high_JJ specific_JJ inhibitory_NN activity_NN of_IN wt-_NN PAI-_NNP 1_CD could_MD
          be_VB due_JJ to_TO the_DT fact_NN that_IN it_PRP was_VBD secreted_JJ from_IN insect_NN
          High-_NNP 5_CD cells_NNS cultured_JJ at_IN 27_CD °_NN C_NNP ,_, while_IN the_DT fibrosarcoma_NN
          preparation_NN of_IN PAI-_NNP 1_CD was_VBD obtained_VBN from_IN the_DT medium_NN of_IN
          fibrosarcoma_NN cells_NNS cultured_JJ at_IN 37_CD °_NN C_NNP [_NN 20_CD ]_NN ._. Exposure_NNP to_TO
          the_DT higher_JJR temperature_NN could_MD accelerate_VB the_DT conversion_NN of_IN
          the_DT inhibitor_NN into_IN its_PRP$ latent_NN form_NN ._.
          The_DT functional_JJ stability_NN of_IN wtPAI-_NN 1_CD and_CC the_DT
          fibrosarcoma_NN PAI-_NNP 1_CD in_IN the_DT absence_NN or_CC in_IN presence_NN of_IN
          vitronectin_NN are_VBP illustrated_VBN in_IN Figure_NN 1_CD C_NNP ._. wtPAI-_NN 1_CD lost_VBD
          its_PRP$ inhibitory_NN activity_NN at_IN the_DT same_JJ pace_NN as_IN the_DT
          fibrosarcoma_NN PAI-_NNP 1_CD ,_, indicating_VBG that_IN its_PRP$ functional_JJ half_JJ
          life_NN as_IN an_DT inhibitor_NN and_CC its_PRP$ ability_NN to_TO be_VB stabilized_VBN by_IN
          vitronectin_NN are_VBP similar_JJ to_TO those_DT of_IN the_DT fibrosarcoma_NN
          PAI-_NNP 1_CD ._.
          The_DT second-order_JJ rate_NN constants_NNS (_( in_IN M_NNP -_: 1_CD s_VBZ -_: 1_CD units_NNS )_) of_IN
          the_DT fibrosarcoma_NN PAI-_NNP 1_CD and_CC the_DT wtPAI-_NN 1_CD towards_IN t-_NN PA_NNP were_VBD
          1_CD ._. 4_CD ±_NN 0_CD ._. 5_CD ×_NN 10_CD 7_CD and_CC 1_CD ._. 7_CD ±_NN 0_CD ._. 6_CD ×_NN 10_CD 7_CD ,_, and_CC towards_IN uPA_NN
          were_VBD 4_CD ._. 1_CD ±_NN 1_CD ._. 4_CD ×_NN 10_CD 7_CD and_CC 4_CD ._. 4_CD ±_NN 1_CD ._. 6_CD ×_NN 10_CD 7_CD ,_, respectively_RB ._.
          These_DT results_NNS show_VBP that_IN the_DT wtPAI-_NN 1_CD could_MD inhibit_VB tPA_NN or_CC
          uPA_NN at_IN the_DT same_JJ rate_NN as_IN the_DT fibrosarcoma_NN PAI-_NNP 1_CD ._. In_IN
          addition_NN ,_, it_PRP is_VBZ known_VBN that_IN PAI-_NNP 1_CD inhibits_NNS either_CC tPA_NN or_CC
          uPA_NN by_IN forming_VBG a_DT 1_CD :_: 1_CD SDS_NNP stable_JJ complex_JJ [_NN 4_CD ]_NN ,_, wtPAI-_NN 1_CD
          indeed_RB could_MD form_VB SDS_NNP stable_JJ complex_NN with_IN tPA_NN or_CC uPA_NN
          (_( Fig_NNP ._. 3_LS A_DT )_) just_RB as_IN fibrosarcoma_NN PAI-_NNP 1_CD ._.
        
        
          Single_NNP site_NN mutations_NNS within_IN the_DT distal_NN hinge_VB of_IN
          PAI-_NNP 1_CD
          Since_IN a_DT proline_NN occurs_VBZ not_RB only_RB in_IN position_NN 357_CD of_IN
          PAI-_NNP 1_CD ,_, but_CC also_RB in_IN the_DT corresponding_JJ position_NN of_IN several_JJ
          other_JJ serpins_NNS (_( Table_NNP 1_LS )_) we_PRP attempted_VBD to_TO find_VB out_IN how_WRB does_VBZ
          a_DT mutation_NN of_IN P_NN 357_CD affect_VB the_DT inhibitory_NN activity_NN of_IN
          PAI-_NNP 1_CD ._. Mutant_NNP of_IN Pro_FW 357_CD Gly_NNP blocked_VBD the_DT inhibitory_NN
          activity_NN of_IN PAI-_NNP 1_CD (_( Fig_NNP ._. 2_LS A_DT )_) ._. Similarly_RB ,_, a_DT mutation_NN into_IN
          proline_NN of_IN either_DT Asp_NNP 355_CD or_CC Arg_NNP 356_CD also_RB inactivated_JJ the_DT
          inhibitor_NN ._. It_PRP should_MD be_VB noted_VBN that_IN all_PDT these_DT mutants_NNS
          could_MD be_VB activated_VBN to_TO a_DT similar_JJ extent_NN by_IN 6_CD M_NNP Gnd-_NNP HCl_NNP
          (_( ~_NN 20_CD %_NN inhibitory_NN activity_NN of_IN the_DT wtPAI-_NN 1_CD ,_, activated_VBN under_IN
          the_DT same_JJ conditions_NNS )_) ._. These_DT results_NNS suggest_VBP that_IN a_DT single_JJ
          site_NN mutation_NN at_IN either_DT one_CD of_IN the_DT positions_NNS 355_CD ,_, 356_CD or_CC
          357_CD significantly_RB inactivates_NNS PAI-_NNP 1_CD ._.
          To_TO elucidate_NN the_DT mechanism_NN through_IN which_WDT such_JJ
          mutations_NNS affect_VBP the_DT activity_NN of_IN PAI-_NNP 1_CD ,_, we_PRP determined_VBD
          their_PRP$ effect_NN on_IN the_DT functional_JJ stability_NN of_IN PAI-_NNP 1_CD and_CC on_IN
          its_PRP$ ability_NN to_TO form_VB an_DT SDS_NNP stable_JJ complex_NN with_IN either_DT tPA_NN
          or_CC uPA_NN ._. As_IN seen_VBN in_IN Fig_NNP ._. 2_LS B_NNP ,_, the_DT rate_NN of_IN the_DT spontaneous_JJ
          inactivation_NN of_IN the_DT inhibitor_NN was_VBD significantly_RB increased_VBN
          upon_IN mutation_NN :_: the_DT functional_JJ half_JJ life_NN of_IN the_DT mutants_NNS
          Asp_NNP 355_CD Pro_FW ,_, Arg_NNP 356_CD Pro_FW and_CC Pro_FW 357_CD Gly_NNP was_VBD 23_CD ._. 8_CD ±_NN 4_CD ._. 5_CD min_NN ,_,
          26_CD ._. 2_LS ±_NN 3_CD ._. 7_CD min_NN and_CC 24_CD ._. 7_CD ±_NN 4_CD ._. 8_CD min_NN ,_, respectively_RB ,_, while_IN
          that_DT of_IN wtPAI-_NN 1_CD was_VBD 89_CD ._. 8_CD ±_NN 8_CD ._. 7_CD min_NN ._. Interestingly_RB ,_, there_EX
          was_VBD no_DT significant_JJ difference_NN between_IN the_DT mutants_NNS tested_VBN
          and_CC the_DT wtPAI-_NN 1_CD in_IN their_PRP$ ability_NN to_TO inactivate_NN either_CC tPA_NN
          or_CC uPA_NN (_( Table_NNP 3_LS )_) ._. They_PRP could_MD also_RB form_VB SDS-stable_NNP
          complexes_NNS with_IN tPA_NN or_CC uPA_NN just_RB as_RB well_RB as_IN wtPAI-_NN 1_CD (_( Fig_NNP ._.
          3_LS A_DT )_) ._.
          An_DT interesting_JJ structural_JJ similarity_NN among_IN several_JJ
          serpins_NNS is_VBZ known_VBN to_TO occur_VB at_IN the_DT position_NN corresponding_JJ
          to_TO 355_CD in_IN PAI-_NNP 1_CD ._. While_IN in_IN PAI-_NNP 1_CD this_DT position_NN
          accommodates_NNS a_DT negatively_RB charged_VBN aspartic_JJ acid_NN residue_NN ,_,
          in_IN other_JJ serpins_NNS it_PRP sometimes_RB accommodates_NNS its_PRP$ non_NN
          charged_VBD analog_NN asparagine_NN (_( Table_NNP 1_LS )_) ._. Asp_NNP 355_CD His_PRP$ ,_,
          Asp_NNP 355_CD Lys_NNP ,_, Asp_NNP 355_CD Glu_NNP ,_, Asp_NNP 355_CD Gln_NNP and_CC Asp_NNP 355_CD Asn_NNP were_VBD
          prepared_VBN and_CC used_VBN to_TO show_VB that_IN the_DT negatively_RB charged_VBN
          aspartic_JJ acid_NN in_IN PAI-_NNP 1_CD is_VBZ essential_JJ (_( though_IN not_RB
          sufficient_JJ )_) for_IN its_PRP$ inhibitory_NN activity_NN ._. Mutation_NNP of_IN
          Asp_NNP 355_CD by_IN asparagine_NN (_( the_DT non_NN charged_VBD analog_NN of_IN aspartic_JJ
          acid_NN )_) ,_, or_CC by_IN histidine_NN or_CC lysine_NN (_( that_WDT have_VBP a_DT positively_RB
          charged_VBN side_NN chain_NN )_) or_CC by_IN alanine_NN (_( neutral_JJ )_) ,_, inactivated_JJ
          PAI-_NNP 1_CD ._. Replacement_NNP of_IN this_DT aspartic_JJ acid_NN residue_NN even_RB by_IN
          the_DT negatively_RB charged_VBN glutamic_JJ acid_NN (_( a_DT very_RB close_JJ analog_NN
          of_IN aspartic_JJ acid_NN )_) did_VBD not_RB significantly_RB suffice_VB to_TO
          restore_VB a_DT full_JJ inhibitory_NN activity_NN of_IN PAI-_NNP 1_CD (_( Fig_NNP ._. 3_LS B_NNP )_) ._.
          After_IN activation_NN with_IN 6_CD M_NNP Gnd-_NNP HCl_NNP ,_, each_DT of_IN the_DT six_CD
          mutants_NNS exhibited_VBN a_DT relatively_RB high_JJ inhibitory_NN activity_NN ,_,
          but_CC their_PRP$ specific_JJ activities_NNS were_VBD still_RB much_RB lower_JJR than_IN
          that_DT of_IN wtPAI-_NN 1_CD (_( Fig_NNP ._. 3_LS B_NNP )_) ._. Among_IN them_PRP ,_, Asp_NNP 355_CD Lys_NNP (_( 5_CD ._. 1_LS ±_NN
          4_CD ._. 1_CD U_NNP /_NN ug_NN )_) had_VBD the_DT lowest_JJS specific_JJ activity_NN ,_, while_IN the_DT
          Asp_NNP 355_CD Asn_NNP (_( 20_CD ±_NN 4_CD ._. 2_CD U_NNP /_NN μg_NN )_) had_VBD the_DT highest_JJS specific_JJ
          activity_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. Although_IN they_PRP had_VBD lower_JJR specific_JJ
          activities_NNS ,_, all_DT of_IN the_DT mutants_NNS mentioned_VBN above_IN could_MD
          still_RB form_VB SDS-stable_NNP complexes_NNS with_IN tPA_NN or_CC uPA_NN just_RB as_IN
          the_DT wtPAI-_NN 1_CD (_( data_NNS not_RB shown_VBN )_) ._.
          Two_CD additional_JJ mutations_NNS ,_, Arg_NNP 356_CD Ala_NNP and_CC Arg_NNP 356_CD Glu_NNP ,_,
          were_VBD prepared_VBN to_TO further_VB elucidate_NN the_DT role_NN of_IN Arg_NNP 356_CD ._.
          The_DT specific_JJ inhibitory_NN activity_NN of_IN Arg_NNP 356_CD Ala_NNP was_VBD 7_CD ._. 2_CD ±_NN
          2_CD ._. 5_CD U_NNP /_NN μg_NN ,_, while_IN Arg_NNP 356_CD Glu_NNP exhibited_VBN essentially_RB no_DT
          inhibitory_NN activity_NN ._. This_DT specific_JJ activity_NN was_VBD increased_VBN
          to_TO 35_CD ._. 4_LS ±_NN 8_CD ._. 7_CD U_NNP /_NN ug_NN for_IN Arg_NNP 356_CD Ala_NNP and_CC 6_CD ._. 4_CD ±_NN 2_CD ._. 3_CD U_NNP /_NN μg_NN for_IN
          Arg_NNP 356_CD Glu_NNP after_IN denature_NN and_CC refolding_VBG ._. Just_RB like_IN
          ARG_NNP 356_CD Pro_FW ,_, Arg_NNP 356_CD Ala_NNP and_CC Arg_NNP 356_CD Glu_NNP were_VBD much_RB more_JJR labile_NN
          than_IN wtPAI-_NN 1_CD ._. These_DT results_NNS suggest_VBP that_IN the_DT role_NN of_IN the_DT
          Asp_NNP 355_CD -_: Pro_FW 357_CD segment_NN is_VBZ to_TO stabilize_VB the_DT inhibitory_NN
          conformation_NN of_IN PAI-_NNP 1_CD ._.
        
        
          Specific_JJ activity_NN ,_, functional_JJ stability_NN and_CC complex_JJ
          formation_NN of_IN Glu_NNP 351_CD Ala_NNP and_CC Glu_NNP 351_CD Arg_NNP
          The_DT specific_JJ inhibitory_NN activities_NNS of_IN wtPAI-_NN 1_CD ,_,
          Glu_NNP 351_CD Ala_NNP and_CC Glu_NNP 351_CD Arg_NNP were_VBD assessed_VBN with_IN uPA_NN and_CC
          S-_NNP 2444_CD ._. As_IN shown_VBN in_IN Fg_NNP ._. 4_LS A_DT ,_, the_DT specificity_NN of_IN wtPAI-_NN 1_CD ,_,
          Glu_NNP 351_CD Ala_NNP and_CC Glu_NNP 351_CD Arg_NNP after_IN denatured_JJ by_IN 6_CD M_NNP Gdn-_NNP HCl_NNP
          and_CC dialyzed_JJ against_IN 50_CD mM_NN sodium_NN acetate_NN ,_, pH_NN 5_CD ._. 6_CD ,_, was_VBD 84_CD
          ±_NN 15_CD ,_, 112_CD ±_NN 18_CD and_CC 68_CD ±_NN 9_CD U_NNP /_NN ug_NN ,_, respectively_RB ._. Glu_NNP 351_CD Ala_NNP
          had_VBD a_DT higher_JJR ,_, and_CC Glu_NNP 351_CD Arg_NNP lower_JJR specific_JJ activity_NN than_IN
          wtPAI-_NN 1_CD ._. The_DT specific_JJ activities_NNS of_IN PAI-_NNP 1_CD s_VBZ determined_VBN
          immediately_RB after_IN purification_NN displayed_VBD similar_JJ pattern_NN
          as_IN that_DT of_IN inhibitors_NNS reactivated_VBD ._. There_RB was_VBD about_IN 15_CD -_: 20_CD %_NN
          increase_NN after_IN reactivation_NN compared_VBN to_TO each_DT untreated_JJ
          protein_NN itself_PRP ._. As_IN shown_VBN in_IN Fig_NNP ._. 4_LS B_NNP ,_, the_DT two_CD mutants_NNS also_RB
          spontaneously_RB lost_VBD their_PRP$ inhibitory_NN activity_NN (_( convert_VB to_TO
          latency_NN )_) as_IN wtPAI-_NN 1_CD ,_, but_CC at_IN different_JJ rates_NNS ._. The_DT
          functional_JJ stability_NN of_IN wtPAI-_NN 1_CD ,_, Glu_NNP 351_CD Ala_NNP ,_, Glu_NNP 351_CD Arg_NNP was_VBD
          about_IN 18_CD ±_NN 5_CD ,_, 90_CD ±_NN 8_CD and_CC 14_CD ±_NN 3_CD minutes_NNS ,_, respectively_RB ._. It_PRP
          suggested_VBD that_IN the_DT specific_JJ activities_NNS measured_VBN above_IN ,_, to_TO
          some_DT extent_NN ,_, proportionally_RB represent_VB the_DT functional_JJ
          stability_NN ._. More_RBR importantly_RB ,_, amount_NN complexes_NNS formed_VBN by_IN
          tPA_NN and_CC PAI-_NNP 1_CD s_VBZ remained_VBN after_IN incubation_NN at_IN 37_CD °_NN C_NNP (_( Fig_NNP ._.
          4_LS C_NNP )_) were_VBD proportionally_RB concordant_NN with_IN the_DT results_NNS
          obtained_VBN from_IN enzymatic_JJ stability_NN assay_NN (_( Fig_NNP ._. 4_LS B_NNP )_) ._. This_DT
          proves_VBZ that_IN results_NNS from_IN enzymatic_JJ assay_NN are_VBP valid_JJ ._. The_DT
          result_NN of_IN functional_JJ stability_NN suggests_VBZ that_IN Glu_NNP 351_CD is_VBZ
          indeed_RB involved_VBN in_IN the_DT conformational_NN transition_NN of_IN
          PAI-_NNP 1_CD ._.
        
        
          Inhibition_NNP of_IN thrombin_NN by_IN PAI-_NNP 1_CD s_VBZ and_CC Neutralization_NNP
          of_IN PAI-_NNP 1_CD s_VBZ by_IN Thrombin_NNP
          Both_DT mutants_NNS inhibited_VBD thrombin_NN more_RBR efficiently_RB than_IN
          wtPAI-_NN 1_CD ,_, more_RBR importantly_RB ,_, Glu_NNP 351_CD Ala_NNP was_VBD better_JJR than_IN
          Glu_NNP 351_CD Arg_NNP in_IN inhibiting_VBG thrombin_NN (_( Fig_NNP ._. 5_LS A_DT )_) ;_: Inhibition_NNP of_IN
          thrombin_NN by_IN Glu_NNP 351_CD Arg_NNP was_VBD almost_RB as_RB same_JJ as_IN by_IN Glu_NNP 351_CD Ala_NNP
          in_IN presence_NN of_IN vitronectin_NN (_( Fig_NNP ._. 5_LS B_NNP )_) ,_, which_WDT facilitated_JJ
          the_DT thrombin_NN inhibition_NN by_IN both_DT mutants_NNS ._. When_WRB excess_JJ
          equal_JJ amount_NN of_IN thrombin_NN was_VBD incubated_JJ with_IN equal_JJ amount_NN
          of_IN PAI-_NNP 1_CD s_VBZ in_IN term_NN of_IN inhibitory_NN activity_NN against_IN uPA_NN ,_,
          mutant_JJ inhibitors_NNS were_VBD neutralized_VBN faster_RBR by_IN thrombin_NN
          than_IN wtPAI-_NN 1_CD ,_, and_CC vitronectin_NN also_RB facilitated_JJ the_DT
          neutralization_NN of_IN Glu_NNP 351_CD Ala_NNP or_CC Glu_NNP 351_CD Arg_NNP by_IN thrombin_NN ,_,
          just_RB similar_JJ to_TO the_DT wtPAI-_NN 1_CD (_( Fig_NNP ._. 5_LS C_NNP )_) ._.
        
        
          Inhibition_NNP of_IN plasmin_NN by_IN PAI-_NNP 1_CD s_VBZ
          When_WRB plasmin_NN was_VBD incubated_JJ with_IN increased_VBN amount_NN of_IN
          equal_JJ active_JJ PAI-_NNP 1_CD s_VBZ in_IN absence_NN or_CC in_IN presence_NN of_IN
          vitronectin_NN ,_, it_PRP was_VBD inhibited_VBD faster_JJR by_IN mutants_NNS than_IN by_IN
          wtPAI-_NN 1_CD (_( Fig_NNP ._. 6_CD upper_JJ panel_NN )_) ;_: and_CC both_DT of_IN mutant_JJ also_RB
          displayed_VBN improved_VBN inhibition_NN toward_IN plasmin_NN in_IN presence_NN
          of_IN vitronectin_NN (_( Fig_NNP ._. 6_CD lower_JJR panel_NN )_) ._.
        
        
          Kinetic_NNP analysis_NN
          The_DT rate_NN constants_NNS of_IN tPA_NN for_IN wtPAI-_NN 1_CD ,_, Glu_NNP 351_CD Ala_NNP and_CC
          Glu_NNP 351_CD Arg_NNP were_VBD similar_JJ (_( Table_NNP 4_LS )_) ,_, however_RB ,_, The_DT rate_NN
          constants_NNS of_IN inhibition_NN toward_IN uPA_NN by_IN Glu_NNP 351_CD Ala_NNP and_CC
          Glu_NNP 351_CD Arg_NNP were_VBD 4_CD and_CC 7_CD -_: fold_VB higher_JJR than_IN by_IN wtPAI-_NN 1_CD ,_,
          respectively_RB ._. Moreover_RB ,_, The_DT rate_NN constants_NNS of_IN Glu_NNP 351_CD Ala_NNP
          and_CC Glu_NNP 351_CD Arg_NNP for_IN thrombin_NN inhibition_NN were_VBD 2_CD to_TO 4_CD folds_NNS
          higher_JJR than_IN that_DT of_IN wtPAI-_NN 1_CD and_CC rate_NN constants_NNS of_IN
          Glu_NNP 351_CD Ala_NNP and_CC Glu_NNP 351_CD Arg_NNP to_TO plasmin_NN were_VBD 2_CD fold_VB higher_JJR
          than_IN that_DT of_IN wtPAI-_NN 1_CD ._. This_DT indicates_VBZ that_IN Glu_NNP 351_CD is_VBZ not_RB
          essential_JJ for_IN the_DT interaction_NN with_IN tPA_NN ,_, but_CC it_PRP is_VBZ an_DT very_RB
          important_JJ determinant_NN for_IN the_DT optimal_NN interaction_NN with_IN
          uPA_NN ,_, thrombin_NN and_CC plasmin_NN ._.
        
      
      
        Disscusion_NNP
        
          Cognate_NNP protease_NN specificity_NN
          Improvements_NNP in_IN specificity_NN of_IN mutants_NNS for_IN uPA_NN
          indicates_VBZ that_IN Glu_NNP 351_CD involve_VB in_IN the_DT interaction_NN with_IN
          uPA_NN ._. To_TO the_DT best_JJS of_IN our_PRP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ time_NN
          that_IN the_DT specificity_NN of_IN PAI-_NNP 1_CD toward_IN uPA_NN is_VBZ partially_RB
          mediated_JJ by_IN the_DT negatively_RB charged_VBN residue_NN located_VBN in_IN the_DT
          C-_NNP terminal_NN of_IN cleavage_NN site_NN in_IN PAI-_NNP 1_CD ._. The_DT interaction_NN of_IN
          Glu_NNP 351_CD with_IN uPA_NN is_VBZ much_RB more_RBR important_JJ than_IN that_DT of_IN
          Glu_NNP 351_CD with_IN tPA_NN ,_, which_WDT is_VBZ demonstrated_VBN by_IN improved_VBN
          reactivity_NN of_IN Glu_NNP 351_CD mutants_NNS toward_IN uPA_NN ,_, but_CC not_RB toward_IN
          tPA_NN ,_, showing_VBG that_DT tPA_NN is_VBZ not_RB directly_RB interact_NN with_IN
          Glu_NNP 351_CD of_IN PAI-_NNP 1_CD ,_, whereas_IN Glu_NNP 351_CD is_VBZ necessary_JJ for_IN the_DT
          optimal_NN interaction_NN with_IN uPA_NN ._. Our_PRP$ results_NNS are_VBP concordant_NN
          with_IN previous_JJ study_NN ,_, [_NN 25_CD ]_NN which_WDT suggests_VBZ that_DT serpin_NN
          body-protease_JJ body_NN interactions_NNS play_VBP significant_JJ roles_NNS in_IN
          determining_VBG serpin_NN inhibitory_NN activity_NN against_IN target_NN
          proteases_NNS ._.
        
        
          Non-cognate_NNP protease_NN
          Substitution_NNP of_IN Glu_NNP 351_CD also_RB altered_VBD the_DT specificity_NN
          toward_IN non-cognate_JJ proteases_NNS :_: plasmin_NN and_CC thrombin_NN ._. Glu_NNP
          at_IN 351_CD may_MD provide_VB steric_JJ hindrance_NN that_WDT slows_VBZ the_DT rate_NN
          of_IN thrombin_NN or_CC plasmin_NN inhibition_NN ._. Mutations_NNP at_IN Glu_NNP 351_CD
          may_MD decrease_VB the_DT original_JJ repulsive_JJ interactions_NNS with_IN
          variable_JJ region_NN of_IN thrombin_NN ,_, which_WDT may_MD slow_VB the_DT rate_NN of_IN
          thrombin_NN inhibition_NN ,_, or_CC results_NNS in_IN favorable_JJ interactions_NNS
          that_WDT may_MD not_RB exist_VB when_WRB wtPAI-_NN 1_CD react_VB with_IN thrombin_NN ._. So_RB ,_,
          both_DT Glu_NNP 351_CD Arg_NNP and_CC Glu_NNP 351_CD Arg_NNP are_VBP better_JJR thrombin_NN
          inhibitors_NNS than_IN wtPAI-_NN 1_CD ._. Similar_JJ results_NNS were_VBD observed_VBN
          for_IN plasmin_NN ._. With_IN single_JJ mutation_NN at_IN position_NN Glu_NNP 351_CD ,_, we_PRP
          improved_VBD reactivity_NN of_IN PAI-_NNP 1_CD to_TO thrombin_NN and_CC plasmin_NN
          without_IN significantly_RB affecting_VBG its_PRP$ specificity_NN to_TO tPA_NN ._.
          This_DT substantiates_NNS previous_JJ mutagenesis_NNS studies_NNS ,_, which_WDT
          demonstrated_VBD that_IN repulsive_JJ interactions_NNS and_CC /_NN or_CC lack_NN of_IN
          productive_JJ electrostatic_JJ interactions_NNS between_IN Glu_NNP 39_CD and_CC
          Glu_NNP 192_CD of_IN thrombin_NN and_CC PAI-_NNP 1_CD are_VBP responsible_JJ for_IN the_DT slow_JJ
          reaction_NN of_IN thrombin_NN with_IN this_DT serpin_NN ._. [_NN 26_CD ]_NN
          Furthermore_RB ,_, the_DT rapid_JJ inhibition_NN of_IN plasmin_NN requires_VBZ a_DT
          non-covalent_JJ interaction_NN between_IN an_DT amino-terminal_JJ site_NN
          of_IN plasmin_NN and_CC a_DT carboxyl-terminal_JJ on_IN anti-plasmin_JJ ,_, and_CC a_DT
          second_JJ site_NN outside_IN the_DT RCL_NNP of_IN PAI-_NNP 1_CD contributes_VBZ to_TO its_PRP$
          specific_JJ interaction_NN with_IN proteases_NNS ._. [_NN 15_CD 27_CD ]_NN The_DT
          specificity_NN of_IN the_DT two_CD mutants_NNS toward_IN thrombin_NN and_CC
          plasmin_NN implicates_NNS that_IN Glu_NNP 351_CD of_IN PAI-_NNP 1_CD is_VBZ involved_VBN in_IN
          its_PRP$ specificity_NN toward_IN thrombin_NN and_CC plasmin_NN ._.
        
      
      
        Conclusion_NNP
        Single_NNP site_NN mutations_NNS within_IN the_DT segment_NN
        Asp_NNP 355_CD -_: Arg_NNP 356_CD -_: Pro_FW 357_CD of_IN PAI-_NNP 1_CD yield_VB Gdn-_NNP HCl_NNP activatable_JJ
        inhibitors_NNS that_WDT can_MD still_RB form_VB SDS_NNP stable_JJ complexes_NNS with_IN
        plasminogen_NN activators_NNS ,_, with_IN second_JJ order_NN inhibition_NN
        constants_NNS that_WDT are_VBP similar_JJ to_TO the_DT native_JJ inhibitor_NN ._.
        Interestingly_RB ,_, the_DT conversion_NN of_IN these_DT mutants_NNS to_TO latent_NN
        forms_NNS was_VBD ~_NN 3_CD -_: 4_CD fold_VB faster_RBR than_IN wtPAI-_NN 1_CD ,_, suggesting_VBG that_IN
        the_DT Asp_NNP 355_CD -_: Pro_FW 357_CD segment_NN is_VBZ involved_VBN in_IN maintaining_VBG the_DT
        inhibitory_NN conformation_NN of_IN PAI-_NNP 1_CD ._. Glu_NNP 351_CD contributes_VBZ to_TO the_DT
        optimal_NN functional_JJ stability_NN of_IN PAI-_NNP 1_CD and_CC participates_VBZ its_PRP$
        conformational_NN stability_NN ._. More_RBR importantly_RB ,_, Glu_NNP 351_CD of_IN PAI-_NNP 1_CD
        is_VBZ a_DT specificity_NN determinant_NN for_IN uPA_NN ,_, thrombin_NN and_CC plasmin_NN ,_,
        but_CC not_RB for_IN tPA_NN ._.
      
      
        Methods_NNP
        
          General_NNP DNA_NNP techniques_NNS
          Plasmid_NNP DNA_NNP was_VBD purified_JJ using_VBG either_CC Promega_NNP or_CC
          QIAGEN_NNP miniprep_NN kits_NNS ._. The_DT DNA_NNP was_VBD sequenced_JJ using_VBG the_DT
          di-deoxy_JJ chain_NN termination_NN reaction_NN method_NN using_VBG an_DT ABI_NNP
          373_CD DNA_NNP sequencer_NN ._. Oligonucleotides_NNP were_VBD synthesized_JJ
          using_VBG a_DT 380_CD B_NNP DNA_NNP synthesizer_NN (_( ABI_NNP model_NN )_) ._. DNA_NN
          manipulation_NN techniques_NNS were_VBD carried_VBN out_IN according_VBG to_TO
          standard_JJ procedures_NNS [_NN 29_CD ]_NN ._.
        
        
          Construction_NNP of_IN wtPAI-_NN 1_CD and_CC its_PRP$ mutants_NNS
          The_DT pPAI-_NN 1_CD -_: AI_NNP was_VBD digested_VBN with_IN EcoRI_NNP and_CC BglII_NNP to_TO
          release_VB a_DT 1426_CD basepair_NN (_( bp_NN )_) PAI-_NNP 1_CD coding_VBG sequence_NN ,_, which_WDT
          was_VBD isolated_VBN ,_, purified_JJ ,_, and_CC ligated_JJ into_IN EcoRI_NNP and_CC BglII_NNP
          digested_VBN pVL_NN 1393_CD ._. The_DT resultant_JJ pVL_NN 1393_CD -_: PAI-_NNP 1_CD was_VBD
          analyzed_VBN by_IN restriction_NN mapping_NN and_CC sequencing_VBG ._. The_DT
          mutants_NNS at_IN E_NNP 351_CD A_DT ,_, E_NNP 351_CD R_NN ,_, D_NNP 355_CD ,_, R_NN 356_CD ,_, and_CC P_NN 357_CD of_IN PAI-_NNP 1_CD
          were_VBD generated_VBN by_IN PCR_NNP ._. The_DT occurrence_NN of_IN the_DT resulting_VBG
          mutations_NNS D_NNP 355_CD A_DT ,_, D_NNP 355_CD E_NNP ,_, D_NNP 355_CD H_NNP ,_, D_NNP 355_CD K_NNP ,_, D_NNP 355_CD N_NNP ,_, D_NNP 355_CD P_NN ,_,
          D_NNP 355_CD Q_NNP ,_, R_NN 356_CD P_NN ,_, P_NN 357_CD G_NNP as_RB well_RB as_IN E_NNP 351_CD A_DT and_CC E_NNP 351_CD R_NN in_IN pRSET_NN
          was_VBD confirmed_VBN by_IN sequencing_VBG ._. The_DT PAI-_NNP 1_CD sequence_NN
          containing_VBG the_DT desired_VBN mutations_NNS was_VBD digested_VBN with_IN EcoR_NNP 1_CD
          and_CC BglII_NNP ,_, and_CC then_RB subcloned_JJ into_IN pVL_NN 1393_CD ._. The_DT
          recombinant_JJ baculoviruses_NNS containing_VBG either_CC wtPAI-_NN 1_CD ,_, or_CC
          one_CD of_IN the_DT above_JJ mutants_NNS was_VBD obtained_VBN as_IN deccribed_JJ by_IN
          Kjoller_NNP et_CC al_NN ._. [_NN 30_CD ]_NN
        
        
          Expression_NNP and_CC purification_NN of_IN wtPAI-_NN 1_CD and_CC its_PRP$
          mutants_NNS
          High_NNP 5_CD cells_NNS ,_, grown_VBN at_IN 27_CD °_NN C_NNP in_IN SF-_NNP 900_CD serum-free_JJ
          medium_NN ,_, were_VBD infected_VBN with_IN high-titer_JJ virus_NN stocks_NNS (_( 1_CD -_: 3_CD ×_NN
          10_CD 8_CD /_NN ml_NN )_) ._. The_DT medium_NN was_VBD collected_VBN 48_CD hrs_NNS after_IN the_DT
          infection_NN (_( found_VBD to_TO be_VB the_DT optimal_NN harvesting_NN time_NN for_IN
          wtPAI-_NN 1_LS )_) and_CC then_RB centrifuged_JJ for_IN 5_CD minutes_NNS (_( 125_CD ×_NN g_SYM )_) ._.
          The_DT supernatents_NNS (_( 50_CD ml_NN )_) were_VBD collected_VBN and_CC sodium_NN
          chloride_NN (_( final_JJ concentration_NN 0_CD ._. 25_CD M_NNP )_) was_VBD added_VBN ._. They_PRP
          were_VBD then_RB applied_VBN on_IN a_DT heparin-_NN Sepharose_NNP column_NN (_( bed_NN
          volume_NN 5_CD ml_NN )_) that_WDT was_VBD equilibrated_JJ and_CC run_VB (_( flow_NN rate_NN 20_CD
          ml_NN /_NN h_NN )_) with_IN a_DT buffer_NN consisted_VBD of_IN 50_CD mM_NN sodium_NN acetate_NN ,_, pH_NN
          5_CD ._. 6_CD ,_, containing_VBG 0_CD ._. 25_CD M_NNP NaCl_NNP and_CC 0_CD ._. 01_CD %_NN Tween-_NNP 20_CD ._. The_DT
          columns_NNS were_VBD washed_VBN and_CC the_DT PAI-_NNP 1_CD s_VBZ were_VBD eluted_JJ with_IN a_DT 40_CD
          ml_NN gradient_NN of_IN 0_CD ._. 25_CD -_: 1_CD M_NNP NaCl_NNP in_IN the_DT same_JJ buffer_NN ._.
        
        
          SDS-PAGE_NNP ,_, immunoblotting_VBG and_CC deglycosylation_NN of_IN
          PAI-_NNP 1_CD
          The_DT medium_NN of_IN the_DT infected_JJ cells_NNS and_CC the_DT elutent_NN from_IN
          heparin-_NN Sepharose_NNP were_VBD separated_JJ on_IN 10_CD %_NN SDS-PAGE_NNP ,_, and_CC
          monitored_VBN by_IN silver_NN staining_VBG ._. Fibrosarcoma_NNP PAI-_NNP 1_CD and_CC
          wtPAI-_NN 1_CD were_VBD transferred_VBN onto_IN nitrocellulose_NN paper_NN and_CC
          the_DT proteins_NNS were_VBD revealed_VBN with_IN anti-human_JJ PAI-_NNP 1_CD
          monoclonal_NN antibodies_NNS ,_, followed_VBN by_IN horseradish_NN peroxidase_NN
          (_( HRP_NNP )_) conjugated_JJ rabbit_NN anti-mouse_JJ antibody_NN ,_, and_CC enhanced_JJ
          chemiluminescence_NN (_( ECL_NNP )_) ._. 5_LS ug_NN of_IN Fibrosarcoma_NNP PAI-_NNP 1_CD ,_, or_CC
          wtPAI-_NN 1_CD was_VBD denatured_JJ by_IN boiling_VBG for_IN 5_CD min_NN in_IN a_DT buffer_NN
          consisted_VBD of_IN 0_CD ._. 5_CD %_NN SDS_NNP ,_, 50_CD mM_NN β-mercaptoethanol_JJ and_CC 50_CD mM_NN
          Tris-_NNP HCl_NNP ,_, pH_NN 7_CD ._. 4_CD ._. They_PRP were_VBD then_RB digested_VBN (_( 18_CD hr_NN ,_, at_IN
          37_CD °_NN C_NNP )_) with_IN 0_CD ._. 5_CD units_NNS of_IN recombinant_JJ N-_NNP glycanase_NN in_IN the_DT
          presence_NN of_IN 2_CD ._. 5_CD %_NN NP-_NNP 40_CD ,_, and_CC subjected_VBN to_TO SDS-PAGE_NNP and_CC
          silver_NN staining_VBG ._. Protein_NNP concentrations_NNS were_VBD determined_VBN
          by_IN the_DT Bio-_NNP Rad_NNP protein_NN assay_NN reagent_NN ._.
        
        
          Functional_NNP stability_NN of_IN fibrosarcoma_NN PAI-_NNP 1_CD ,_, wtPAI-_NN 1_CD
          and_CC its_PRP$ mutants_NNS
          The_DT inhibitory_NN activities_NNS of_IN fibrosarcoma_NN PAI-_NNP 1_CD ,_,
          wtPAI-_NN 1_CD ,_, and_CC its_PRP$ mutants_NNS were_VBD measured_VBN by_IN a_DT direct_JJ
          chromogenic_JJ assay_NN using_VBG uPA_NN (_( 100_CD U_NNP /_NN ug_NN )_) and_CC its_PRP$ substrate_NN
          S-_NNP 2444_CD in_IN a_DT microtiter_NN plate_NN as_IN described_VBN earlier_JJR [_NN 20_CD ]_NN
          ._. Briefly_NNP ,_, fibrosarcoma_NN PAI-_NNP 1_CD ,_, wtPAI-_NN 1_CD ,_, or_CC its_PRP$ mutants_NNS
          were_VBD diluted_VBN 1_CD :_: 10_CD in_IN the_DT activity_NN measuring_VBG assay_NN buffer_NN
          (_( 50_CD uM_NN Tris-_NNP HCl_NNP ,_, pH_NN 7_CD ._. 5_CD ,_, containing_VBG 0_CD ._. 15_CD M_NNP NaCl_NNP and_CC 100_CD
          ug_NN /_NN ml_NN BSA_NNP )_) ._. The_DT PAI-_NNP 1_CD samples_NNS were_VBD incubated_JJ in_IN the_DT
          absence_NN or_CC in_IN the_DT presence_NN of_IN a_DT two_CD molar_NN excess_NN of_IN
          vitronectin_NN (_( the_DT fibrosarcoma_NN PAI-_NNP 1_CD and_CC the_DT wtPAI-_NN 1_CD were_VBD
          incubated_JJ with_IN vitronectin_NN )_) at_IN 37_CD °_NN C_NNP ._. At_IN the_DT times_NNS
          indicated_VBD ,_, aliquots_NNS were_VBD removed_VBN and_CC analyzed_VBN immediately_RB
          for_IN their_PRP$ inhibitory_NN activity_NN ._. One_CD unit_NN of_IN PAI-_NNP 1_CD activity_NN
          is_VBZ defined_VBN as_IN the_DT amount_NN that_WDT completely_RB neutralizes_VBZ 1_CD U_NNP
          of_IN uPA_NN ._. The_DT specific_JJ activity_NN obtained_VBN at_IN time_NN zero_CD was_VBD
          assigned_VBN a_DT value_NN of_IN 100_CD %_NN ._.
        
        
          Activation_NNP of_IN PAI-_NNP 1_CD and_CC kinetic_JJ analysis_NN
          Fibrosarcoma_NNP PAI-_NNP 1_CD ,_, wtPAI-_NN 1_CD or_CC its_PRP$ mutants_NNS were_VBD
          denatured_JJ with_IN 6_CD M_NNP guanidine-hydrochloride_JJ (_( Gdn-_NNP HCl_NNP )_) (_( 45_CD
          min_NN at_IN 37_CD °_NN C_NNP )_) ,_, followed_VBN by_IN dialysis_NN (_( 4_CD -_: 16_CD hours_NNS at_IN 4_CD °_NN C_NNP )_)
          against_IN 50_CD mM_NN sodium_NN acetate_NN ,_, pH_NN 5_CD ._. 6_CD ,_, containing_VBG 0_CD ._. 5_CD M_NNP
          NaCl_NNP and_CC 0_CD ._. 01_CD %_NN Tween-_NNP 20_CD ._. This_DT process_NN which_WDT PAI-_NNP 1_CD
          regained_VBD its_PRP$ activity_NN is_VBZ called_VBN activation_NN by_IN Gdn-_NNP HCl_NNP ._.
          The_DT inhibitory_NN activity_NN of_IN each_DT of_IN the_DT PAI-_NNP 1_CD s_VBZ was_VBD assayed_JJ
          immediately_RB ._. The_DT second-order_JJ rate_NN constants_NNS for_IN the_DT
          interaction_NN of_IN the_DT fibrosarcoma_NN PAI-_NNP 1_CD ,_, wtPAI-_NN 1_CD or_CC the_DT
          indicated_VBD mutants_NNS with_IN single-chain_JJ tPA_NN or_CC uPA_NN were_VBD
          determined_VBN in_IN a_DT single-step_JJ assay_NN as_RB previously_RB
          described_VBD ._. [_NN 20_CD ]_NN
        
        
          Specific_JJ activity_NN ,_, functional_JJ stability_NN and_CC complex_JJ
          formation_NN of_IN PAI-_NNP 1_CD s_VBZ
          The_DT inhibitory_NN activities_NNS of_IN wtPAI-_NN 1_CD and_CC mutants_NNS were_VBD
          measured_VBN by_IN a_DT direct_JJ chromogenic_JJ assay_NN using_VBG uPA_NN (_( 100_CD
          U_NNP /_NN μg_NN )_) and_CC substrate_NN S-_NNP 2444_CD ._. [_NN 17_CD ]_NN Briefly_NNP ,_, serially_RB
          diluted_VBN wtPAI-_NN 1_CD ,_, or_CC mutants_NNS were_VBD incubated_JJ with_IN equal_JJ
          volume_NN of_IN uPA_NN (_( 50_CD μl_NN ,_, 50_CD U_NNP /_NN ml_NN )_) for_IN 30_CD min_NN at_IN 37_CD °_NN C_NNP ,_,
          followed_VBN by_IN addition_NN of_IN 100_CD μl_NN ,_, 0_CD ._. 5_CD mM_NN S-_NNP 2444_CD ._. Residual_NNP
          uPA_NN activity_NN was_VBD quantitated_JJ by_IN measuring_VBG the_DT change_NN in_IN
          absorbance_NN at_IN 405_CD nm_NN with_IN ELISA_NNP reader_NN ._. The_DT specific_JJ
          activity_NN of_IN PAI-_NNP 1_CD was_VBD calculated_VBN based_VBN on_IN the_DT amount_NN of_IN
          uPA_NN inhibited_VBD by_IN PAI-_NNP 1_CD ._. The_DT assay_NN for_IN PAI-_NNP 1_CD inhibitory_NN
          activity_NN toward_IN two-chain_JJ tPA_NN was_VBD the_DT same_JJ for_IN uPA_NN except_IN
          that_IN the_DT samples_NNS were_VBD incubated_JJ with_IN tPA_NN and_CC S-_NNP 2288_CD ._.
          PAI-_NNP 1_CD inhibitory_NN activity_NN is_VBZ expressed_VBN as_IN the_DT number_NN of_IN
          international_JJ units_NNS of_IN PAs_NNP inhibited_VBD by_IN PAI-_NNP 1_CD ._. Specific_JJ
          activity_NN of_IN uPA_NN and_CC two-chain_JJ tPA_NN are_VBP 100_CD U_NNP /_NN μg_NN and_CC 764_CD
          U_NNP /_NN μg_NN ,_, respectively_RB ._. For_IN the_DT functional_JJ stability_NN ,_,
          wtPAI-_NN 1_CD ,_, or_CC mutants_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP ._. Aliquots_NNP were_VBD
          taken_VBN out_RB at_IN times_NNS indicated_VBD and_CC analyzed_VBD immediately_RB as_IN
          described_VBN above_IN ._. The_DT specific_JJ activity_NN obtained_VBN at_IN time_NN
          zero_CD was_VBD assigned_VBN a_DT value_NN of_IN 100_CD %_NN ._. To_TO provide_VB the_DT
          evidence_NN to_TO support_VB the_DT conclusion_NN obtained_VBN from_IN enzyme_NN
          assay_NN ,_, certain_JJ amount_NN of_IN wtPAI-_NN 1_CD ,_, E_NNP 351_CD R_NN and_CC E_NNP 351_CD A_DT were_VBD
          incubated_JJ with_IN equal_JJ amount_NN of_IN tPA_NN at_IN 37_CD °_NN C_NNP for_IN 30_CD minutes_NNS
          before_IN put_NN on_IN ice_NN ,_, at_IN same_JJ time_NN these_DT PAI-_NNP 1_CD s_VBZ were_VBD
          incubated_JJ in_IN PBS_NNP at_IN 37_CD °_NN C_NNP for_IN 3_CD hours_NNS ,_, respectively_RB ,_,
          before_IN the_DT PAI-_NNP 1_CD s_VBZ were_VBD incubated_JJ with_IN same_JJ amount_NN of_IN tPA_NN
          at_IN 37_CD °_NN C_NNP for_IN 30_CD minutes_NNS ,_, then_RB the_DT protein_NN samples_NNS prepared_VBN
          at_IN two_CD time_NN points_NNS were_VBD subjected_VBN to_TO SDS-PAGE_NNP and_CC western_JJ
          blot_NN as_IN described_VBN before_RB ._.
        
        
          Inhibition_NNP of_IN thrombin_NN and_CC plasmin_NN by_IN PAI-_NNP 1_CD s_VBZ
          Thrombin_NNP (_( 0_CD ._. 025_CD U_NNP )_) ,_, or_CC plasmin_NN (_( 0_CD ._. 1_LS μg_NN /_NN ml_NN )_) was_VBD
          incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 30_CD min_NN with_IN same_JJ amount_NN of_IN wtPAI-_NN 1_CD ,_,
          E_NNP 351_CD A_DT and_CC E_NNP 351_CD R_NN in_IN term_NN of_IN inhibitory_NN activity_NN toward_IN uPA_NN
          (_( 20_CD U_NNP in_IN the_DT concentration_NN range_NN of_IN 4_CD -_: 10_CD μg_NN /_NN ml_NN )_) in_IN
          absence_NN or_CC presence_NN of_IN vitronectin_NN (_( 60_CD μg_NN /_NN ml_NN )_) ._. Linear_NNP
          increase_NN of_IN absorbance_NN at_IN 405_CD nm_NN were_VBD recorded_VBN after_IN
          adding_VBG S-_NNP 2238_CD (_( final_JJ concentration_NN 0_CD ._. 25_CD mM_NN )_) for_IN thrombin_NN ,_,
          or_CC N-_NNP p-_NN Tosyl-_NNP Gly-_NNP Pro-_NNP Lys-p-_NNP Nitroanilide_NNP (_( final_JJ
          concentration_NN 0_CD ._. 5_CD mM_NN )_) for_IN plasmin_NN ._. Thrombin_NNP ,_, or_CC plasmin_NN
          activity_NN without_IN PAI-_NNP 1_CD was_VBD taken_VBN as_IN 100_CD %_NN ._.
        
        
          Neutralization_NNP of_IN PAI-_NNP 1_CD s_VBZ by_IN Thrombin_NNP
          wtPAI-_NN 1_CD and_CC mutants_NNS were_VBD incubated_JJ with_IN four_CD molar_NN
          excess_NN of_IN thrombin_NN (_( 40_CD nM_NN )_) in_IN the_DT absence_NN or_CC presence_NN of_IN
          vitronectin_NN (_( 30_CD nM_NN )_) ._. Control_NN experiments_NNS were_VBD carried_VBN out_IN
          in_IN the_DT absence_NN of_IN thrombin_NN ._. After_IN 20_CD min_NN at_IN 37_CD °_NN C_NNP ,_, the_DT
          activity_NN of_IN thrombin_NN was_VBD quenched_JJ by_IN the_DT addition_NN of_IN
          hirudin_NN (_( final_JJ concentration_NN ,_, 60_CD units_NNS /_NN ml_NN )_) ,_, resulting_VBG in_IN
          inhibition_NN of_IN more_JJR than_IN 95_CD %_NN of_IN the_DT amidolytic_JJ activity_NN of_IN
          thrombin_NN ._. Subsequently_RB ,_, the_DT residual_JJ PAI-_NNP 1_CD inhibitory_NN
          activity_NN was_VBD determined_VBN by_IN titration_NN of_IN aliquots_NNS on_IN uPA_NN ,_,
          using_VBG S_NNP 2444_CD as_IN substrate_NN ._. The_DT increase_NN of_IN the_DT optical_JJ
          density_NN at_IN 405_CD nm_NN in_IN the_DT samples_NNS was_VBD corrected_VBN for_IN the_DT
          values_NNS measured_VBN with_IN (_( hirudin-inactivated_JJ )_) thrombin_NN
          alone_RB ,_, since_IN the_DT amidolytic_JJ activity_NN of_IN thrombin_NN on_IN S_NNP 2444_CD
          was_VBD not_RB completely_RB blocked_VBN by_IN hirudin_NN ,_,
        
        
          Complex_JJ formation_NN of_IN PAI-_NNP 1_CD s_VBZ with_IN tPA_NN or_CC uPA_NN
          Complex_JJ formation_NN of_IN the_DT fibrosarcoma_NN PAI-_NNP 1_CD ,_, wtPAI-_NN 1_CD
          or_CC its_PRP$ mutants_NNS with_IN single-chain_JJ tPA_NN or_CC uPA_NN were_VBD
          performed_VBN as_IN described_VBN earlier_JJR [_NN 20_CD ]_NN ._. Samples_NNP of_IN PAI-_NNP 1_CD s_VBZ
          (_( 5_CD U_NNP )_) were_VBD incubated_JJ in_IN the_DT absence_NN or_CC in_IN the_DT presence_NN of_IN
          a_DT 2_CD -_: fold_VB excess_NN of_IN uPA_NN or_CC tPA_NN in_IN the_DT activity_NN assay_NN
          buffer_NN ._. Following_VBG a_DT 30_CD min_NN incubation_NN at_IN room_NN
          temperature_NN ,_, the_DT samples_NNS were_VBD subjected_VBN to_TO a_DT 10_CD %_NN SDS-PAGE_NNP
          and_CC immunoblotting_VBG as_IN described_VBN above_IN ._.
        
      
      
        Abbreviations_NNP
        tPA_NN ,_, tissue-type_JJ plasminogen_NN activator_NN ;_: uPA_NN ,_,
        urokinase-type_JJ plasminogen_NN activator_NN ;_: PAI-_NNP 1_CD ,_, plasminogen_NN
        activator_NN inhibitor_NN type_NN 1_CD ;_: serpin_NN ,_, serine_NN protease_NN
        inhibitor_NN ;_: RCL_NNP ,_, reactive_JJ center_NN loop_NN ;_: Vn_NNP ,_, vitronectin_NN ,_, SDS_NNP ,_,
        sodium_NN dodecylsulfate_NN ;_: PAGE_NNP ,_, polyacrylamide_NN gel_NN
        electrophoresis_NNS ._. Gdn-_NNP HCl_NNP ,_, guanidine-hydrochloride_JJ ;_: HRP_NNP ,_,
        horseradish_NN peroxidase_NN ;_: ECL_NNP ,_, enhanced_JJ chemiluminescence_NN ;_:
        PBS_NNP ,_, phosphate-buffered_JJ saline_NN ;_: BSA_NNP ,_, bovine_JJ serum_NN
        albumin_NN ._.
      
      
        Authors_NNP '_'' contribution_NN
        Qingcai_NNP Wang_NNP carried_VBD out_RP the_DT experiments_NNS and_CC drafted_VBD the_DT
        manuscript_NN ;_:
        Professor_NNP Shmuel_NNP Shaltiel_NNP sponsored_VBD and_CC supervised_VBD the_DT
        project_NN and_CC revised_VBD the_DT manuscript_NN ._.
      
    
  
